Profile for recalfidoositep
|
SignatureTizanidine is a central alpha-2 adrenergic receptor agonist and was first considered as a viable treatment for TN in a double-blind study comparing itThe tizanidine patients were individually titrated to pain relief with the maintenance dose ranging from 6 to 18 mg per day. The study showed that...
|
